Go here to learn more or to get a mailed copy.
Home » Bio » YI Awards » YI Award Recipients 2013
Growing evidence points to a link between..
Lu Yang, MD:
West China Hospital, Sichuan University
Qiang Wei, MD and Tianyong Fan, MD
Treating inflammation to prevent prostate cancer initiation and progression.
Growing clinical evidence suggests that a majority..
Shalini S. Yadav, PhD:
Mount Sinai School of Medicine
Ashutosh Tewari, MD
Intratumor Heterogeneity (ITH) in Prostate Cancer
Dr. Eliezer Van Allen is an Assistant..
Treatment of advanced, metastatic prostate cancer, although..
Daniel Thorek, PhD:
Johns Hopkins University
David Scheinberg, MD, PhD and Steve Larson, MD
Alpha-particle therapy by 225Actinium-labeled prostate kallikrein-specific antibody to eradicate advanced disease
IGF (Insulin-like Growth Factor) receptor is dysregulated..
Nicole Simone, MD:
Thomas Jefferson University
Adam Dicker, MD, PhD, Karen Knudsen, PhD and Peter Carroll, MD
Metabolic approaches for targeting multiple components of the IGF-1R pathway in prostate cancer
Deficiencies in the repair of DNA are..
Matthew Schiewer, PhD:
Karen Knudsen, PhD
Determining the translation capacity of the PARP-1/AR axis in prostate cancer
Low vitamin D levels in blood have..
Jennifer Rider, ScD:
Harvard School of Public Health
Lorelei Mucci, ScD and Myles Brown, MD
The immunomodulatory and androgen-associated actions of vitamin D in prostate cancer
Colin Pritchard, MD, PhD:
University of Washington
Peter Nelson, MD
Targeting the ‘Hypermutated Subtype’ of Prostate Cancer: From Mechanism to Implementation of Genomic Testing for Precision Therapy”
Angiogenesis is the process of new blood..
Niv Papo, PhD:
Ben-Gurion University of the Negev (Israel)
Eyal Mishani, PhD
Developing novel dual-specific proteins that target multiple receptors for applications in prostate cancer imaging and therapy
Systems biology is a computational-based inter-disciplinary field..
Antonina Mitrofanova, PhD:
Rutgers, The State University of New Jersey
Michael Shen, PhD
A systems biology approach to identify and evaluate novel drug targets for aggressive prostate cancer
LncRNAs (long non-coding RNAs) are a form..
Rohit Mehra, MD:
University of Michigan School of Medicine
Arul Chinnaiyan, MD, PhD
Clinicopathological characterization of novel lncRNAs in prostate cancer risk stratification
Dr. Aaron LeBeau is an Assistant Professor..
2013 PCF Young Investigator Award
Certain oncogenic molecules in prostate cancer cells..
Theodoros Karantanos, MD:
MD Anderson Cancer Center
Timothy Thompson, PhD and Christopher Logothetis, MD
The role of aerobic glycolysis in the development of castrate resistant prostate cancer
Dr. Hu’s research program will focus on..
Hao Hu, MD, MBBS:
People’s Hospital, Peking University
Kexin Xu, MD, MBBS and Xiaofeng Wang, MBBS
EMI1 and its role in prostate cancer initiation and progression.
Preclinical assessment of mechanisms of resistance to..
Vivek Arora, MD, PhD:
Charles Sawyers, MD
Defining strategies to overcome enzalutamide (Xtandi) resistance
Approximately 25% of patients who fail Xtandi..
Jennifer Bishop, PhD:
University of British Columbia
Martin Gleave, MD and Amina Zoubeidi, PhD
Regulation of cell plasticity by the androgen receptor: A novel mechanism of enzalutamide (Xtandi) resistance
The organization of DNA into super-structures is..
Irfan Asangani, PhD:
University of Michigan
Characterization and therapeutic targeting of MMSET in prostate cancer
A family of proteins known as the..
Qi Cao, PhD:
Houston Methodist Research Institute
A novel role for Polycomb Group proteins in androgen signaling and prostate cancer
Engraftment of prostate cancer in bone heralds..
Charles Chan, PhD:
Stanford University School of Medicine
Irving Weissman, MD and Michael Longaker, MD
Identification and therapeutic targeting of cancer stem cell niche interactions in metastatic prostate bone marrow disease
An unmet medical need is the control..
Chia-Yi Chu, PhD:
Cedars-Sinai Medical Center
Leland Chung, PhD
Metastasis-initiating cells (MICs) as predictors of lethal progression of human prostate cancer
Molecular imaging of prostate cancer to determine..
Michael Evans, PhD:
University of California, San Francisco
Charles Sawyers, MD and Jason Lewis, PhD
Exploiting the genetics of advanced prostate cancer for tumor detection and therapy with transferrin-based radionuclides
Jason A. Efstathiou, MD, DPhil:
Massachusetts General Hospital
Matthew R. Smith, MD, PhD
Predictors of Response and Failure to Radiotherapy for Prostate Cancer in a Randomized Trial
Proteomics is the study of proteins in..
Geraldine Gueron, PhD:
Elba Vazquez, PhD
Proteome-base biomarkers in prostate cancer: protein profiling using mass spectrometry, bioinformatics based approach and tissue microarray technology
Immunotherapy has come of age with the..
Philip Kantoff, MD and Christopher Sweeney, MBBS
Clinical exploration of innovative targeted and immune modulating therapies in prostate cancer
Understanding resistance to new treatments for advanced,..
Emmanuel Antonarakis, MD:
Johns Hopkins University School of Medicine
Michael Carducci, MD and Jun Luo, PhD
Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.
Over 1 million prostate biopsies are performed..
Syed Adnan Ali, MD:
Intratumor Heterogeneity (ITH) in Prostate Cancer